U.S. markets close in 2 hours 1 minute
  • S&P 500

    3,844.92
    -25.37 (-0.66%)
     
  • Dow 30

    31,456.14
    +64.62 (+0.21%)
     
  • Nasdaq

    13,092.44
    -266.34 (-1.99%)
     
  • Russell 2000

    2,243.19
    +11.68 (+0.52%)
     
  • Crude Oil

    61.64
    +1.89 (+3.16%)
     
  • Gold

    1,716.60
    -17.00 (-0.98%)
     
  • Silver

    26.37
    -0.51 (-1.89%)
     
  • EUR/USD

    1.2076
    -0.0012 (-0.10%)
     
  • 10-Yr Bond

    1.4720
    +0.0570 (+4.03%)
     
  • GBP/USD

    1.3971
    +0.0014 (+0.10%)
     
  • USD/JPY

    106.9590
    +0.2490 (+0.23%)
     
  • BTC-USD

    51,252.24
    +3,343.26 (+6.98%)
     
  • CMC Crypto 200

    1,026.08
    +37.99 (+3.84%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,559.10
    +150.93 (+0.51%)
     

Liquidia to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
Liquidia Technologies, Inc.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT® technology, today announced that Neal Fowler, Chief Executive Officer of Liquidia, will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020 at 10:20am Eastern time.

A link to the live audio webcast and replay of the presentation will be available on the Events & Presentations page of the Company’s corporate website, and will be archived for a minimum of 90 days.

About Liquidia

Liquidia is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology to transform the lives of patients. PRINT is a particle engineering platform that enables precise production of uniform drug particles designed to improve the safety, efficacy and performance of a wide range of therapies. Currently, Liquidia is focused on the development of two product candidates for which it holds worldwide commercial rights: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. Liquidia is headquartered in Research Triangle Park, NC. For more information, please visit www.liquidia.com.

Contact Information

Investor Relations:
Jason Adair
Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com